The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The game-changing drug, Truvada – the only drug approved for PrEP – will be offered to groups considered at risk of HIV.
The European Commission has given pharmaceutical company, Gilead, the green light to market Truvada as pre-exposure prophylaxis (PrEP) across the region.
National Health Service (NHS) England has decided against providing pre-exposure prophylaxis (PrEP) for HIV-negative people at a high risk of HIV, sparking outrage among a number of HIV charities and service providers in the UK.
The United States of America has in December, quietly and partially lifted their ban on federal funding for needle and syringe exchange programmes (NSPs).